Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERVIPIB: Gemcitabine and Brachytherapy in Cervical Cancer
NCT02957266Phase 3Unknown
- Sponsor
- National Center of Oncology
- Start
- Mar 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in Cervical Cancer (CC) (2 arms), sponsored by National Center of Oncology. Primary endpoints: Relapse Rate (local and/or distant) at 4 years and Number of Deaths Due to Any Cause at 4 years. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02957266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957266.